DrJaguar8
commented on
$Theriva Biologics (TOVX.US)$ I had this in my notes and as Y’all know on Fridays i leave for the day about 9:15AM est! And i was intending to give Y’all a “Heads-Up” This was coming! And apologies because i got busy and it slipped my mind! And before the usual hate comes! Hehehe That says “Yeah right, you could take credit now like you knew! Hehehe And part of that would be correct! I did not know if it would for sure move or not! But as many know my Heads-Ups are...
8
10
DrJaguar8
reacted to and commented on
⚠️READ THIS BEFORE YOU TRADE ⚠️
1. NFA — Nothing here is financial advice. I am not your financial advisor, and this is NOT a buy/sell alert.
2. Trade with confirmation. Always check the chart, volume, momentum, order book, and short availability before touching a position.
3. Manage risk like a pro. Scale out, take profits, use stops. If you’re guessing instead of planning, you’re gambling.
4. Your P&L is yours. Wins are yours to celebrate, loss...
1. NFA — Nothing here is financial advice. I am not your financial advisor, and this is NOT a buy/sell alert.
2. Trade with confirmation. Always check the chart, volume, momentum, order book, and short availability before touching a position.
3. Manage risk like a pro. Scale out, take profits, use stops. If you’re guessing instead of planning, you’re gambling.
4. Your P&L is yours. Wins are yours to celebrate, loss...
9
7
DrJaguar8
commented on
$VolitionRX (VNRX.US)$ any thoughts on the RS? should i sell at a loss now or hold 😢😢😢
3
DrJaguar8
commented on
$Theriva Biologics (TOVX.US)$
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
by Globe Newswire
Follow
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver me...
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
by Globe Newswire
Follow
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver me...
1
2
$Faraday Future Intelligent Electric Inc. (FFAI.US)$
Press Release: AIxCrypto's Designated Investor and Faraday Future Complete Amendment to $12 Million Investment Agreement,Exploring RWA-Related Applications and Integration of Real-World Assets With Blockchain Infrastructure
Press Release: AIxCrypto's Designated Investor and Faraday Future Complete Amendment to $12 Million Investment Agreement,Exploring RWA-Related Applications and Integration of Real-World Assets With Blockchain Infrastructure
1
$Hyperscale Data (GPUS.US)$
Press Release: Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock
Dow Jones
Hyperscale Data Also Declares Monthly Cash Dividend of $0.20833 per Share of 10.00% Series E Cumulative Redeemable Perpetual Preferred Stock
LAS VEGAS, April 17, 2026 /PRNewswire/ -- Hyperscale Data, Inc. (NYSE American: GPUS), an artificial intelligence ("AI") data center company anchored by Bitcoin ("...
Press Release: Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock
Dow Jones
Hyperscale Data Also Declares Monthly Cash Dividend of $0.20833 per Share of 10.00% Series E Cumulative Redeemable Perpetual Preferred Stock
LAS VEGAS, April 17, 2026 /PRNewswire/ -- Hyperscale Data, Inc. (NYSE American: GPUS), an artificial intelligence ("AI") data center company anchored by Bitcoin ("...
1
1
$Agenus (AGEN.US)$
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
by Business Wire
Follow
First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal cancer shows disease control rate (DCR) of 77% in patients and long-term survival beyond 20 months in a subset of heavily pretreated patients
Induction strategy linked to improvem...
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
by Business Wire
Follow
First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal cancer shows disease control rate (DCR) of 77% in patients and long-term survival beyond 20 months in a subset of heavily pretreated patients
Induction strategy linked to improvem...
1
$Evaxion A/S (EVAX.US)$
Evaxion's AI-Immunology Platform Demonstrates 86% Vaccine Target Precision in Phase 2 Personalized Cancer Vaccine Trial
GlobeNewswire
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response
The results reinforce that Evaxion's pioneering AI platform,
AI-Immunology accurately identifies and selects the most relevant vaccine targets
Data will be presented at the America...
Evaxion's AI-Immunology Platform Demonstrates 86% Vaccine Target Precision in Phase 2 Personalized Cancer Vaccine Trial
GlobeNewswire
New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response
The results reinforce that Evaxion's pioneering AI platform,
AI-Immunology accurately identifies and selects the most relevant vaccine targets
Data will be presented at the America...
For the newer traders, take time to learn from this Stock Education I compiled since last year
STOCK EDUCATION & SITES: Compiled - DrJaguar8
STOCK EDUCATION & SITES: Compiled - DrJaguar8
28
10
DrJaguar8
liked
$Able View Global (ABLV.US)$ 55.46%
$Blaize Holdings (BZAI.US)$ 32%
$Cosmos Health (COSM.US)$ 18.04%
$iSpecimen (ISPC.US)$ 54.60%
$Nauticus Robotics (KITT.US)$ 30%
$MYSEUM.AI INC (MYSE.US)$ 41.86%
$Psyence Biomedical (PBM.US)$ 61.02%
$Snail (SNAL.US)$ 29.21%
$WeShop (WSHP.US)$ 48.77%
$YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS (YXT.US)$ 54.07%
$Blaize Holdings (BZAI.US)$ 32%
$Cosmos Health (COSM.US)$ 18.04%
$iSpecimen (ISPC.US)$ 54.60%
$Nauticus Robotics (KITT.US)$ 30%
$MYSEUM.AI INC (MYSE.US)$ 41.86%
$Psyence Biomedical (PBM.US)$ 61.02%
$Snail (SNAL.US)$ 29.21%
$WeShop (WSHP.US)$ 48.77%
$YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS (YXT.US)$ 54.07%
13
3
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,PHN2ZyB3aWR0aD0iMjYiIGhlaWdodD0iMjYiIHZpZXdCb3g9IjAgMCAyNiAyNiIgZmlsbD0ibm9uZSIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj4KPHBhdGggZmlsbC1ydWxlPSJldmVub2RkIiBjbGlwLXJ1bGU9ImV2ZW5vZGQiIGQ9Ik0xMi45OTk5IDAuMzI1NDM5QzYuMDQxMTEgMC4zMjU0MzkgMC4zOTk5MDIgNS45NjY2NSAwLjM5OTkwMiAxMi45MjU0QzAuMzk5OTAyIDE5Ljg4NDIgNi4wNDExMSAyNS41MjU0IDEyLjk5OTkgMjUuNTI1NFYyMi43MjU0QzcuNTg3NTEgMjIuNzI1NCAzLjE5OTkgMTguMzM3OCAzLjE5OTkgMTIuOTI1NEMzLjE5OTkgNy41MTMwNSA3LjU4NzUxIDMuMTI1NDQgMTIuOTk5OSAzLjEyNTQ0VjAuMzI1NDM5WiIgZmlsbD0idXJsKCNwYWludDBfbGluZWFyXzIyMDBfNDg2NikiLz4KPHBhdGggZmlsbC1ydWxlPSJldmVub2RkIiBjbGlwLXJ1bGU9ImV2ZW5vZGQiIGQ9Ik0xMyAyNS41MjU0QzE5Ljk1ODggMjUuNTI1NCAyNS42IDE5Ljg4NDIgMjUuNiAxMi45MjU0QzI1LjYgNS45NjY2NSAxOS45NTg4IDAuMzI1NDQgMTMgMC4zMjU0MzlWMy4xMjU0NEMxOC40MTI0IDMuMTI1NDQgMjIuOCA3LjUxMzA1IDIyLjggMTIuOTI1NEMyMi44IDE4LjMzNzggMTguNDEyNCAyMi43MjU0IDEzIDIyLjcyNTRWMjUuNTI1NFoiIGZpbGw9InVybCgjcGFpbnQxX2xpbmVhcl8yMjAwXzQ4NjYpIi8+CjxjaXJjbGUgY3g9IjEzLjAwMDEiIGN5PSIyNC4xMjUzIiByPSIxLjQiIGZpbGw9InVybCgjcGFpbnQyX2xpbmVhcl8yMjAwXzQ4NjYpIi8+CjxkZWZzPgo8bGluZWFyR3JhZGllbnQgaWQ9InBhaW50MF9saW5lYXJfMjIwMF80ODY2IiB4MT0iNy4zOTk5IiB5MT0iMjUuNTI1NCIgeDI9IjcuMzk5OSIgeTI9IjIuNDI1NDQiIGdyYWRpZW50VW5pdHM9InVzZXJTcGFjZU9uVXNlIj4KPHN0b3Agc3RvcC1jb2xvcj0iIzdBN0E3QSIgc3RvcC1vcGFjaXR5PSIwIi8+CjxzdG9wIG9mZnNldD0iMSIgc3RvcC1jb2xvcj0iIzdBN0E3QSIgc3RvcC1vcGFjaXR5PSIwLjUiLz4KPC9saW5lYXJHcmFkaWVudD4KPGxpbmVhckdyYWRpZW50IGlkPSJwYWludDFfbGluZWFyXzIyMDBfNDg2NiIgeDE9IjIwIiB5MT0iMjUuNTI1NCIgeDI9IjIwIiB5Mj0iMi40MjU0NCIgZ3JhZGllbnRVbml0cz0idXNlclNwYWNlT25Vc2UiPgo8c3RvcCBzdG9wLWNvbG9yPSIjN0E3QTdBIi8+CjxzdG9wIG9mZnNldD0iMSIgc3RvcC1jb2xvcj0iIzdBN0E3QSIgc3RvcC1vcGFjaXR5PSIwLjUiLz4KPC9saW5lYXJHcmFkaWVudD4KPGxpbmVhckdyYWRpZW50IGlkPSJwYWludDJfbGluZWFyXzIyMDBfNDg2NiIgeDE9IjEzLjAwMDEiIHkxPSIyNC4xMjUzIiB4Mj0iMTQuNDAwMSIgeTI9IjI0LjEyNTMiIGdyYWRpZW50VW5pdHM9InVzZXJTcGFjZU9uVXNlIj4KPHN0b3Agc3RvcC1jb2xvcj0iIzdBN0E3QSIvPgo8c3RvcCBvZmZzZXQ9IjEiIHN0b3AtY29sb3I9IiM3QTdBN0EiIHN0b3Atb3BhY2l0eT0iMCIvPgo8L2xpbmVhckdyYWRpZW50Pgo8L2RlZnM+Cjwvc3ZnPgo=)
DrJaguar8 Trytosaveabit OP : Hi brother! Thanks for the kind words. So far, no verbal haters so far this year. I think they know they get reported. I hope you had a good day with Paps!
DrJaguar8 Trytosaveabit OP : I had PT today and quite tired because i did some timed walking exercise. Then headed to the beach as usual to just breathe some ocean air. How was dinner last night?